MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Interventions"

  • 2024 International Congress

    Preventing Medication Errors for Hospitalized People with Parkinson’s Disease – Results of Six Months of Proactive Intervention

    C. Piccinin, J. Yu, A. Brooks, V. Stepanyants, P. Clark, S. Shaffer, B. Sokola, K. Lewin, C. Sonneborn, O. Hogue, S. Sperling, H. Fernandez, W. Walter (Cleveland, USA)

    Objective: To determine whether a Parkinson’s disease (PD) Inpatient Program will prevent medication errors and ultimately improve the safety and quality of care for hospitalized…
  • 2024 International Congress

    Evaluation of Infusion Site Adverse Events With Foslevodopa/Foscarbidopa in a 12-Week, Randomized Study

    S. Isaacson, R. Kirsner, O. Vaou, R. Pahwa, R. Hauser, L. Bergmann, R. Gupta, M. Shah, S. Varughese, T. Kimber (Boca Raton, USA)

    Objective: To characterize infusion site events (ISEs) in patients with advanced Parkinson’s disease (aPD) treated with foslevodopa/foscarbidopa (LDp/CDp). Background: ISEs, including local reactions and infusion…
  • 2024 International Congress

    Can We Rid Uganda of the Societal Myth That Parkinson’s Disease Is Witchcraft?

    S. Klingelhofer, H. Tamale, G. Mogan (Tillamook, USA)

    Objective: Educate rural Ugandans that Parkinson’s Disease (PD) is a scientific disorder, not contagious or the result of anything mystical Background: People with PD (PWP)…
  • 2024 International Congress

    Non-interventional phase 0 study for the collection of biospecimens from patients with Parkinson’s Disease (PD) to support the development of a diagnostic classifier for LRRK2-driven PD

    L. Desnoyers, S. Dheerendra, C. Wong, T. Dang, S. Esmaeeli, M. van Derbrug, M. Nalls, A. Ellenbogen, S. Jackson (South San Francisco, USA)

    Objective: Measure LRRK2 pathway activity in Parkinson’s Disease patients stratified using a genetic predictive classifier model. Background: Extensive research has shown that overactivation of the…
  • 2024 International Congress

    Comparative-effectiveness of Foscarbidopa/foslevodopa (LDp/CDp) versus Oral Therapies in Advanced Parkinson’s Disease: A Propensity Matched Study

    D. Standaert, A. Fasano, F. Ory-Magne, D. Kern, O. de Fabregues, T. Oeda, D. Safarpour, Z. Baldwin, C. Yan, S. Wang, K. Onuk, P. Kukreja, L. Bergmann, V. Fung (Birmingham, USA)

    Objective: To assess long-term effectiveness outcomes in people with advanced Parkinson’s Disease (aPD) on LDp/CDp versus those on oral PD therapies (standard of care, SoC).…
  • 2024 International Congress

    Palliative Care in Advanced Parkinson’s Disease: Descriptive Analysis and Symptom Impact

    C. Armengol-García, J. Hartmann-Nava, D. Martínez-Ramírez (Monterrey, Mexico)

    Objective: These preliminary study aims to describe the primary clinical features of Parkinson's disease patients requiring palliative care, as assessed by the Edmonton Symptom Assessment…
  • 2024 International Congress

    Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment In Parkinson’s Disease: A Single-Center Retrospective Chart Study

    AA. Vanderplas (Leiderdorp, Netherlands)

    Objective: The objectives of this chart study were to evaluate adaptations in medication and flow rates and adverse events in patients with Parkinson’s disease (PD)…
  • 2023 International Congress

    Effects on voice sound level and brain connectivity after HiCommunication: a novel speech and communication treatment for Parkinson’s disease

    H. Steurer, F. Albrecht, A. Razi, J. Körner Gustafsson, E. Franzén, E. Schalling (Stockholm, Sweden)

    Objective: This study aimed to evaluate the clinical relevance of effects on voice sound level (Lv) as well as brain connectivity using resting-state functional MRI…
  • 2023 International Congress

    Co-designing Digital Technologies to improve Clinical Care in People with Parkinson’s Disease

    M. Monje, S. Grosjean, M. Srp, L. Antunes, R. Bouca-Machado, R. Cacho, S. Rodriguez, J. Inocentes, T. Lynch, A. Tsakanika, D. Fotiadis, G. Rigas, E. Ruzicka, J. Ferreira, A. Antonini, N. Malpica, T. Mestre, A. Sánchez-Ferro (Chicago, USA)

    Objective: To develop a co-design methodology and test the usability and acceptability of three digital health technologies for people with Parkinson’s Disease (PwP) Background: The…
  • 2023 International Congress

    Baseline characteristics for patients with multiple system atrophy entering a randomized, controlled study of the anti-α-synuclein monoclonal antibody Lu AF82422

    W. Singer, A. Takeda, L. Kjærsgaard, J. Wiedemann, A. Berger, A. Varrone, A. Bidani, D. Meulien (Rochester, USA)

    Objective: Report baseline characteristics for patients with multiple system atrophy (MSA) entering a study to assess the safety and efficacy of alpha-synuclein (α-syn) monoclonal antibody…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 23
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley